WO2007149797A3 - Use of organic compounds - Google Patents

Use of organic compounds Download PDF

Info

Publication number
WO2007149797A3
WO2007149797A3 PCT/US2007/071420 US2007071420W WO2007149797A3 WO 2007149797 A3 WO2007149797 A3 WO 2007149797A3 US 2007071420 W US2007071420 W US 2007071420W WO 2007149797 A3 WO2007149797 A3 WO 2007149797A3
Authority
WO
WIPO (PCT)
Prior art keywords
organic compounds
metformin
pharmaceutically acceptable
acceptable salt
effective amount
Prior art date
Application number
PCT/US2007/071420
Other languages
French (fr)
Other versions
WO2007149797A2 (en
Inventor
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Boerk Balkan
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
David Grenville Holmes
Thomas Edward Hughes
Edwin Bernard Villhauer
Boerk Balkan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, David Grenville Holmes, Thomas Edward Hughes, Edwin Bernard Villhauer, Boerk Balkan filed Critical Novartis Ag
Publication of WO2007149797A2 publication Critical patent/WO2007149797A2/en
Publication of WO2007149797A3 publication Critical patent/WO2007149797A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method to prevent, delay the progression or reduce, the Gastrointestinal disorders or Gastrointestinal side effects induced by metformin, comprising administering a therapeutically effective amount of metformin or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of a DPP-IV inhibitor, preferably vildagliptin, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
PCT/US2007/071420 2006-06-19 2007-06-18 Use of organic compounds WO2007149797A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81492106P 2006-06-19 2006-06-19
US60/814,921 2006-06-19

Publications (2)

Publication Number Publication Date
WO2007149797A2 WO2007149797A2 (en) 2007-12-27
WO2007149797A3 true WO2007149797A3 (en) 2008-05-08

Family

ID=38739900

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071420 WO2007149797A2 (en) 2006-06-19 2007-06-18 Use of organic compounds

Country Status (1)

Country Link
WO (1) WO2007149797A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NO347644B1 (en) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorphs
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
AR071175A1 (en) 2008-04-03 2010-06-02 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION THAT INCLUDES AN INHIBITOR OF DIPEPTIDIL-PEPTIDASA-4 (DPP4) AND A COMPARING PHARMACO
KR20200118243A (en) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8865729B2 (en) 2008-12-23 2014-10-21 Boehringer Ingelheim International Gmbh Salt forms of a xanthine compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
CN104906582A (en) 2009-02-13 2015-09-16 勃林格殷格翰国际有限公司 Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
CN106177958A (en) * 2009-02-13 2016-12-07 勃林格殷格翰国际有限公司 Comprise DPP 4 inhibitor (BI 1356) and optionally combine the antidiabetic medicine of other antidiabetic drug
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20190050871A (en) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
AR085689A1 (en) 2011-03-07 2013-10-23 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS OF METFORMIN, LINAGLIPTINE AND AN SGLT-2 INHIBITOR
KR101985384B1 (en) 2011-07-15 2019-06-03 베링거 인겔하임 인터내셔날 게엠베하 Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014102715A1 (en) 2012-12-24 2014-07-03 Ranbaxy Laboratories Limited Pharmaceutical compositions comprising a biguanide and a low dose antidiabetic agent
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHREN B ET AL: "Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 27, no. 12, December 2004 (2004-12-01), pages 2874 - 2880, XP002412952, ISSN: 0149-5992 *
MEIER J J ET AL: "GLP-1, incretin mimetics and DPP 4 inhibitors: New ways in the treatment of type 2 diabetes", CURRENT MEDICINAL CHEMISTRY. IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS, XX, XX, vol. 5, no. 6, 2005, pages 485 - 497, XP009096792, ISSN: 1568-0134 *

Also Published As

Publication number Publication date
WO2007149797A2 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
WO2007149797A3 (en) Use of organic compounds
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2009020802A3 (en) Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2007087431A3 (en) Sublingual fentanyl spray
WO2009017837A3 (en) Sublingual fentanyl spray
WO2011055944A3 (en) Methods for treating fibromyalgia syndrome
WO2011005811A8 (en) Combination therapy for the treatment of diabetes
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
EP1756074A4 (en) 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007017423A3 (en) Pharmaceutical composition comprising a dpp-iv inhibitor
EP1756106A4 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
WO2008070268A3 (en) Pharmaceutical compositions
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
IL198461A0 (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2009117150A3 (en) Method of treating lupus with ceramide derivatives
PL1799199T3 (en) Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
WO2007019153A3 (en) Methods for treating hypertension
MX337396B (en) Method of treating polycystic kidney diseases with ceramide derivatives.
WO2007100561A3 (en) Use of dha and ara in the preparation of a composition for preventing or treating obesity
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798678

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07798678

Country of ref document: EP

Kind code of ref document: A2